[SCHEDULE 13G/A] Avalo Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Patrick J. Crutcher filed an amended Schedule 13G reporting beneficial ownership of 549,467 shares of Avalo Therapeutics, Inc. common stock, representing 4.2% of the 13,152,356 shares outstanding cited from the issuer's August 7, 2025 prospectus. The filing shows the Reporting Person holds sole voting and dispositive power over all reported shares and indicates the position is not held to change or influence control of the company. The filing includes the Reporting Person's address in Atlanta, GA, and a certification that the securities were not acquired in connection with any control transaction.

Insights

Financial Analyst

TL;DR: Passive stake disclosure; position size is modest at 4.2% and below the 5% reporting threshold for activist signaling.

The filing transparently discloses a 549,467-share position representing 4.2% of Avalo's outstanding common stock based on the prospectus share count. The holder reports sole voting and dispositive power, which identifies this as a straightforward, non‑group, passive stake. Because the position is under 5% and the signer certifies no intent to influence control, this disclosure is unlikely to trigger governance changes or force strategic responses from management.

Corporate Governance Expert

TL;DR: Ownership disclosed is material for transparency but not indicative of control or a governance challenge.

The Schedule 13G/A classification and the signed certification emphasize a passive holding. Reporting sole voting and dispositive power clarifies where authority lies for these shares, but at 4.2% the stake does not meet common material thresholds for activist influence. The filing fulfills regulatory disclosure obligations and allows other investors to monitor ownership concentration without signaling imminent governance action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 Par Value

(Title of Class of Securities)

05338F306

(CUSIP Number)

08/06/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

Patrick J. Crutcher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 549,467.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 549,467.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

549,467.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: See Item 2 for additional information.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Drive, Suite 321 Wayne PA 19087
Item 2.
(a)	Name of person filing: This report on Schedule 13G is being filed by Patrick J. Crutcher (the "Reporting Person"). The ownership percentages are based upon 13,152,356 shares of Common Stock outstanding as disclosed in the Issuer's final prospectus filed with the with SEC on August 7, 2025.
(b)	Address or principal business office or, if none, residence: The address for the Reporting Person is: 650 Ponce De Leon Ave., Suite 300 #2347, Atlanta, GA 30308.
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock, $0.001 Par Value
(e)	CUSIP No.: 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 549,467.00
(b)	Percent of class: 4.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 549,467.00
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 549,467.00
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Patrick J. Crutcher

Signature:	/s/ Patrick J. Crutcher
Name/Title:	Patrick J. Crutcher
Date:	08/27/2025

FAQ

What stake in Avalo Therapeutics (AVTX) does Patrick J. Crutcher report?

The filing reports beneficial ownership of 549,467 shares, equal to 4.2% of the 13,152,356 shares outstanding cited.

Does the Schedule 13G/A indicate an intent to control Avalo Therapeutics (AVTX)?

No. The certification states the securities were not acquired to change or influence control of the issuer.

What voting and dispositive powers are reported by the filer?

The Reporting Person reports sole voting power of 549,467 shares and sole dispositive power of 549,467 shares, with no shared powers.

What share count did the filer use to calculate the ownership percentage?

The percentage is based on 13,152,356 shares outstanding as disclosed in Avalo's final prospectus filed August 7, 2025.

When was the Schedule 13G/A signed?

The signature block shows the filing was signed by Patrick J. Crutcher on 08/27/2025.